trial

Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia

NCTId NCT00218231
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 48 (actual)
Sponsored by National Institute on Drug Abuse (NIDA)
Primary completion 2006-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
48 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2004-01
Primary completion
2006-08
Eligibility
ALL · 18 Years · 80 Years

Interventions & indications

Drugs
300 mg/day bupropion-sr0 mg/day bupropion-sr

Sponsors

National Institute on Drug Abuse (NIDA)Lead Sponsor

Investigators

1
Jennifer Tidey, PhDPrincipal Investigator

Sites

2 total
Providence, United StatesProvidence, United States

Linked catalysts

1
Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia — primary completion2006-08

Facts & assertions

4 sourced
Enrollment
48
Phase
PHASE2
Primary Completion Date
2006-08
Status
COMPLETED
relationships
The graph out of here
drug
300 mg/day bupropion-sr
drug
0 mg/day bupropion-sr
drug
lead_sponsor
National Institute on Drug Abuse (NIDA)
company
indication
Tobacco Use Disorder
indication
Schizophrenia
indication
Tobacco Use Disorder
indication
investigator
Jennifer Tidey, PhD
person